Cysteine cathepsins and stefins in head and neck cancer: An update of clinical studies

Radiology and Oncology

Volumn 42, Issue 2, 2008, Pages 69-81

  Strojan, Primož ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cathepsins; Head and neck cancer; Prognosis; Stefins

Indexed keywords

BLEOMYCIN; CATHEPSIN; CATHEPSIN B; CATHEPSIN L; CYSTATIN C; MITOMYCIN C; STEFIN; STEFIN A; STEFIN B;

CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; EXTRACELLULAR MATRIX; HEAD AND NECK CANCER; HUMAN; PROTEIN DEGRADATION; REVIEW; SQUAMOUS CELL CARCINOMA; TISSUE HOMOGENATE; TUMOR GROWTH;

EID: 45249097542     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-008-0006-4     Document Type: Review

References (42)

1. Vokes EE, Weichselbyum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-94.
2. Strojan P. Cathepsins and their endogenous inhibitors in clinical oncology. Radiol Oncol 1996; 30: 120-33.
3. Stoka V, Turk B, Turk V. Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol Chem 2007; 388: 555-60.
4. Kos J, Šmid L, Krašovec M, Svetic B, Lenarcic B, Vrhovec I, et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 1995; 376: 401-5.
5. Budihna M, Strojan P, Šmid L, Skrk J, Vrhovec I, Zupevc A, et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler 1996; 377: 385-90.
6. Strojan P, Budihna M, Šmid L, Vrhovec I, Skrk J. Prognostic significance of cysteine proteinases B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2000; 6: 1052-62.
7. Strojan P, Oblak I, Svetic N, Šmid L, Kos J. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 2004; 90: 1961-8.
8. Lah TT, Kos J, Blejec A, Frkovic-Georgio S, Golouh R, Vrhovec I, et al. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol Oncol Res 1997; 3: 89-99.
9. Knoch H, Werle B, Ebert W, Spiess E. Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int J Oncol 1994; 5: 77-85.
10. Ebert E, Werle B, Jülke B, Kopitar-Jerala N, Kos J, Lah T, et al. Expression of cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997; 421: 259-65.
11. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
12. Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E, et al. Cysteine proteinase inhibitor cystatin A in breast cancer. Cancer Res 1998; 58: 432-6.
13. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000; 6: 505-11.
14. Kos J, Lah T. Role of cystatins and stefins in cancer. In: Zerovnik E, Kopitar-Jerala N, Uversky V, editors. Human stefins and cystatins. New York: Nova Science Publishers, Inc; 2006. p. 233-6.
15. Levičar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovic-Grazio S, et al. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect Prev 2002; 26: 42-9.
16. Lah TT, Kalman E, Najjar D, Gorodetsky E, Brennan P, Somers R, et al. Cells producing cathepsins D, B and L in human breast carcinoma and their association with prognosis. Hum Pathol 2000; 3: 149-60.
17. Krȩcicki T, Siewiński M. Serum cathepsin B-like activity as a potential marker of laryngeal carcinoma. Eur Arch Otorhinolaryngol 1992; 249: 293-5.
18. Bongers V, Konings CH, Grijpma AM, Steen I, Braakhuis BJM, Snow GB. Serum proteinase activities in head and neck squamous cell carcinoma patients. Anticancer Res 1995; 15: 2763-6.
19. Strojan P, Budihna M, Šmid L, Svetic B, Vrhovec I, Škrk J. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 2001; 48: 66-71.
20. Strojan P, Budihna M, Šmid L, Svetic B, Vrhovec I, Kos J, et al. Cathepsin H in squamous cell carcinoma of the head and neck. Radiol Oncol 1999; 33: 143-51.
21. Siewiński M, Krȩcicki T, Jarmułowicz J, Berdowska I. Cysteine proteinase inhibitors in serum of patients with head and neck tumors. Diagn Oncol 1992; 2: 323-6.
22. Strojan P, Svetic B, Šmid L, Kos J. Serum cystatin C in patients with head and neck carcinoma. Clin Chim Acta 2004; 344: 155-61.
23. Vigneswaran N, Zhao W, Dassanayake A, Muller S, Miller DM, Zacharias W. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum Pathol 2000; 31: 931-7.
24. Macabeo-Ong M, Shiboski CH, Silverman S, Ginzinger DG, Dekker N, Wong DT, et al. Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression. Oral Oncol 2003; 39: 638-47.
25. Nikitakis NG, Rivera H, Lopes MA, Siavash H, Reynolds MA, Ord RA, et al. Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinoma with multiple metastatic lymph nodes. Am J Clin Pathol 2003; 119: 574-86.
26. Kawasaki G, Kato Y, Mizuno A. Cathepsin expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors. Orla Surg Oral Med Oral Patol Oral Radiol Endod 2002; 93: 446-54.
27. Strojan P, Aničin A, Svetic B, Pohar M, Šmid L, Kos J. Stefin A and stefin B: markers for prognosis in inoperable squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007; 68: 1335-41.
28. Bossard N, Descotes F, Bremond AG, Bobin Y, De Saint Hilaire P, Golfier F, et al. Keeping data continuous when analyzing the prognostic impact of the tumor marker: an example with cathepsin D in breast cancer. Breast Cancer Res Treat 2003;82:47-59.
29. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR. Immunohistochemical analysis of cathepsin D, B and L in human breast cancer. Hum Pathol 1994; 25: 857-62.
30. Strojnik T, Židanik B, Kos J, Lah TT. Cathepsin B and L are markers for clinically invasive types of meningeomas. Neurosurgery 2001; 48: 598-605.
31. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, et al. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 2002; 94: 3141-9.
32. Kim R, Emi M, Tanabe K, Uchida Y, Arihiro K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 2006; 32: 269-77.
33. Johansson AC, Norberg-Spaak L, Roberg K. Role of lysosomal cathepsins in napthazarin- and Fas-induced apoptosis in oral squamous cell carcinoma cells. Acta Oto-Laryngol 2006; 126: 70-81.
34. Osmak M, Svetic B, Gabrijelčič-Geiger, Skrk J. Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B. Anticancer Res 2001; 21: 481-4.
35. Zajc I, Hreljac I, Lah T. Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res 2006; 26: 3357-64.
36. Gewies A, Grimm S. Cathepsin-B and cathepsin-L expression levels do not correlate with sensitivity of tumor cells to TNF-alpha-mediated apoptosis. Br J Cancer 2003; 89: 1574-80.
37. Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia inhibits TRAIL-induced tumor cell apoptosis: involvement of lysosomal cathepsins. Apoptosis 2007; 12: 125-39.
38. Wickramasinghe NS, Banerjee K, Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia alters cathepsin B/inhibitor profiles in oral carcinoma cell lines. Anticancer Res 2005; 25: 2841-9.
39. Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 42: 701-4.
40. Strojnik T, Kos J, Židanik B, Golouh R, Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999; 5: 559-67.
41. Campo E, Munoz J, Miquel R, Palacín A, Cardesa A, Sloane BF. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 1994; 145: 301-9.
42. Elzagheid A, Kuopio T, Pyrhönen S, Collan Y. Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? Diagn Pathol 2006; 1: 41.